*Optimal dilutions/concentrations should be determined by the researcher.
Not tested in other applications.
The peptide was used in the production of GTX88474.
Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
SXR blocking peptide , PARQ blocking peptide , NR1I2 blocking peptide , ONR1 blocking peptide , PAR1 blocking peptide , PAR blocking peptide , PAR2 blocking peptide , PRR blocking peptide , SAR blocking peptide , BXR blocking peptide
This gene product belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. The encoded protein is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. Several alternatively spliced transcripts encoding different isoforms, some of which use non-AUG (CUG) translation initiation codon, have been described for this gene. Additional transcript variants exist, however, they have not been fully characterized. [provided by RefSeq, Jul 2008]